The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review


Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Glomerulonephritis


Psychiatry related information on Glomerulonephritis


High impact information on Glomerulonephritis


Chemical compound and disease context of Glomerulonephritis


Biological context of Glomerulonephritis


Anatomical context of Glomerulonephritis


Gene context of Glomerulonephritis

  • We report here that these animals show the classical symptoms of SLE, namely the presence of ANA, the deposition of immune complexes in glomeruli and full-blown glomerulonephritis in a Dnase1-dose-dependent manner [25].
  • Aged C57BL/6(B6)-PD-1(-/-) congenic mice spontaneously developed characteristic lupus-like proliferative arthritis and glomerulonephritis with predominant IgG3 deposition, which were markedly accelerated by introduction of a Fas mutation (lpr) [26].
  • Plasminogen and plasminogen activators protect against renal injury in crescentic glomerulonephritis [27].
  • Early death was prevented, and glomerulonephritis severely reduced in IFN-gamma-/- mice [28].
  • We hypothesized that therapy with a mutant human PAI-1 (PAI-1R) that binds to matrix vitronectin but does not inhibit plasminogen activators, would enhance plasmin generation, increase matrix turnover, and decrease matrix accumulation in experimental glomerulonephritis [29].

Analytical, diagnostic and therapeutic context of Glomerulonephritis


  1. IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23. Gharavi, A.G., Yan, Y., Scolari, F., Schena, F.P., Frasca, G.M., Ghiggeri, G.M., Cooper, K., Amoroso, A., Viola, B.F., Battini, G., Caridi, G., Canova, C., Farhi, A., Subramanian, V., Nelson-Williams, C., Woodford, S., Julian, B.A., Wyatt, R.J., Lifton, R.P. Nat. Genet. (2000) [Pubmed]
  2. Mutation of DNASE1 in people with systemic lupus erythematosus. Yasutomo, K., Horiuchi, T., Kagami, S., Tsukamoto, H., Hashimura, C., Urushihara, M., Kuroda, Y. Nat. Genet. (2001) [Pubmed]
  3. Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome. Rao, T.K., Filippone, E.J., Nicastri, A.D., Landesman, S.H., Frank, E., Chen, C.K., Friedman, E.A. N. Engl. J. Med. (1984) [Pubmed]
  4. Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease. Hibbs, M.L., Tarlinton, D.M., Armes, J., Grail, D., Hodgson, G., Maglitto, R., Stacker, S.A., Dunn, A.R. Cell (1995) [Pubmed]
  5. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Isaka, Y., Brees, D.K., Ikegaya, K., Kaneda, Y., Imai, E., Noble, N.A., Border, W.A. Nat. Med. (1996) [Pubmed]
  6. Microcephaly, focal segmental glomerulonephritis and marfanoid habitus in two sibs. Houlston, R.S., Iraggori, S., Murday, V., Scrine, M., Macdermot, K., Slack, J., Rees, L. Clin. Dysmorphol. (1992) [Pubmed]
  7. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Botto, M., Dell'Agnola, C., Bygrave, A.E., Thompson, E.M., Cook, H.T., Petry, F., Loos, M., Pandolfi, P.P., Walport, M.J. Nat. Genet. (1998) [Pubmed]
  8. Beneficial effects of prostaglandin E1 in rapidly progressive glomerulonephritis. Niwa, T., Maeda, K., Asada, H., Yamamoto, M., Yamada, K. N. Engl. J. Med. (1983) [Pubmed]
  9. Studies of immune-complex glomerulonephritis mediated by human thyroglobulin. Jordan, S.C., Buckingham, B., Sakai, R., Olson, D. N. Engl. J. Med. (1981) [Pubmed]
  10. Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Border, W.A., Noble, N.A., Yamamoto, T., Harper, J.R., Yamaguchi, Y., Pierschbacher, M.D., Ruoslahti, E. Nature (1992) [Pubmed]
  11. Autoimmune target in Heymann nephritis is a glycoprotein with homology to the LDL receptor. Raychowdhury, R., Niles, J.L., McCluskey, R.T., Smith, J.A. Science (1989) [Pubmed]
  12. Relapsing polychondritis with glomerulonephritis. Improvement with prednisone and cyclophosphamide. Ruhlen, J.L., Huston, K.A., Wood, W.G. JAMA (1981) [Pubmed]
  13. Plasmapheresis for rapidly progressive glomerulonephritis: the mystique of dramatic intervention. Friedman, E.A. JAMA (1980) [Pubmed]
  14. Mechanism of action of the C4 nephritic factor. Deregulation of the classical pathway of C3 convertase. Gigli, I., Sorvillo, J., Mecarelli-Halbwachs, L., Leibowitch, J. J. Exp. Med. (1981) [Pubmed]
  15. Sera from patients with poststreptococcal glomerulonephritis contain antibodies to glomerular heparan sulfate proteoglycan. Fillit, H., Damle, S.P., Gregory, J.D., Volin, C., Poon-King, T., Zabriskie, J. J. Exp. Med. (1985) [Pubmed]
  16. Inhibition of mesangial cell proliferation and matrix expansion in glomerulonephritis in the rat by antibody to platelet-derived growth factor. Johnson, R.J., Raines, E.W., Floege, J., Yoshimura, A., Pritzl, P., Alpers, C., Ross, R. J. Exp. Med. (1992) [Pubmed]
  17. Major histocompatibility complex class II expression by intrinsic renal cells is required for crescentic glomerulonephritis. Li, S., Kurts, C., Köntgen, F., Holdsworth, S.R., Tipping, P.G. J. Exp. Med. (1998) [Pubmed]
  18. Interleukin-4 protects against a genetically linked lupus-like autoimmune syndrome. Santiago, M.L., Fossati, L., Jacquet, C., Müller, W., Izui, S., Reininger, L. J. Exp. Med. (1997) [Pubmed]
  19. Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with Roscovitine, a novel cyclin-dependent kinase antagonist. Pippin, J.W., Qu, Q., Meijer, L., Shankland, S.J. J. Clin. Invest. (1997) [Pubmed]
  20. Monocyte procoagulant activity in glomerulonephritis associated with systemic lupus erythematosus. Cole, E.H., Schulman, J., Urowitz, M., Keystone, E., Williams, C., Levy, G.A. J. Clin. Invest. (1985) [Pubmed]
  21. Initial events in the formation of immune deposits in passive Heymann nephritis. gp330-anti-gp330 immune complexes form in epithelial coated pits and rapidly become attached to the glomerular basement membrane. Kerjaschki, D., Miettinen, A., Farquhar, M.G. J. Exp. Med. (1987) [Pubmed]
  22. Altered antigen receptor signaling and impaired Fas-mediated apoptosis of B cells in Lyn-deficient mice. Wang, J., Koizumi, T., Watanabe, T. J. Exp. Med. (1996) [Pubmed]
  23. Cell cycle-dependent interleukin 1 gene expression by cultured glomerular mesangial cells. Lovett, D.H., Larsen, A. J. Clin. Invest. (1988) [Pubmed]
  24. Modulation of neutrophil influx in glomerulonephritis in the rat with anti-macrophage inflammatory protein-2 (MIP-2) antibody. Feng, L., Xia, Y., Yoshimura, T., Wilson, C.B. J. Clin. Invest. (1995) [Pubmed]
  25. Features of systemic lupus erythematosus in Dnase1-deficient mice. Napirei, M., Karsunky, H., Zevnik, B., Stephan, H., Mannherz, H.G., Möröy, T. Nat. Genet. (2000) [Pubmed]
  26. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Nishimura, H., Nose, M., Hiai, H., Minato, N., Honjo, T. Immunity (1999) [Pubmed]
  27. Plasminogen and plasminogen activators protect against renal injury in crescentic glomerulonephritis. Kitching, A.R., Holdsworth, S.R., Ploplis, V.A., Plow, E.F., Collen, D., Carmeliet, P., Tipping, P.G. J. Exp. Med. (1997) [Pubmed]
  28. Interferon-gamma is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice. Balomenos, D., Rumold, R., Theofilopoulos, A.N. J. Clin. Invest. (1998) [Pubmed]
  29. A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis. Huang, Y., Haraguchi, M., Lawrence, D.A., Border, W.A., Yu, L., Noble, N.A. J. Clin. Invest. (2003) [Pubmed]
  30. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Border, W.A., Okuda, S., Languino, L.R., Sporn, M.B., Ruoslahti, E. Nature (1990) [Pubmed]
  31. Effect of castration and sex hormone treatment on survival, anti-nucleic acid antibodies, and glomerulonephritis in NZB/NZW F1 mice. Roubinian, J.R., Talal, N., Greenspan, J.S., Goodman, J.R., Siiteri, P.K. J. Exp. Med. (1978) [Pubmed]
  32. The role of nitric oxide in the pathogenesis of spontaneous murine autoimmune disease: increased nitric oxide production and nitric oxide synthase expression in MRL-lpr/lpr mice, and reduction of spontaneous glomerulonephritis and arthritis by orally administered NG-monomethyl-L-arginine. Weinberg, J.B., Granger, D.L., Pisetsky, D.S., Seldin, M.F., Misukonis, M.A., Mason, S.N., Pippen, A.M., Ruiz, P., Wood, E.R., Gilkeson, G.S. J. Exp. Med. (1994) [Pubmed]
  33. Mechanisms of drug-induced lupus. II. T cells overexpressing lymphocyte function-associated antigen 1 become autoreactive and cause a lupuslike disease in syngeneic mice. Yung, R., Powers, D., Johnson, K., Amento, E., Carr, D., Laing, T., Yang, J., Chang, S., Hemati, N., Richardson, B. J. Clin. Invest. (1996) [Pubmed]
  34. Amplification of nitric oxide synthase expression by nitric oxide in interleukin 1 beta-stimulated rat mesangial cells. Mühl, H., Pfeilschifter, J. J. Clin. Invest. (1995) [Pubmed]
WikiGenes - Universities